SOLASCURE Ltd (“SolasCure”), a biotechnology company developing a novel treatment to transform chronic wound care and the U.S. Army Institute of Surgical Research (“USAISR”), today announced a research collaboration to evaluate SolasCure’s investigational product, Aurase Wound Gel, as a means for managing combat wounds.